Prevention of Hepatic Encephalopathy With Mobile Application Based Lactulose Titration
Not Applicable
Completed
- Conditions
- Hepatic Encephalopathy
- Interventions
- Other: Dieta mobile application
- Registration Number
- NCT05526404
- Lead Sponsor
- Mayo Clinic
- Brief Summary
This study is being done to assess the safety and efficacy of using mobile application-based Bristol stool scale to titrate lactulose in prevention episodes of hepatic encephalopathy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
- Ability to provide written, informed consent.
- Currently taking lactulose daily for prevention of hepatic encephalopathy.
Read More
Exclusion Criteria
- Recent change in dosing of opioid medication.
- Previous Colorectal Surgery.
- Active diarrheal illness.
- Lack of smartphone or other smart device at home.
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Mobile application-based Bristol stool scale Dieta mobile application Subjects with cirrhosis who are taking lactulose for the treatment of hepatic encephalopathy will download the Dieta mobile application on their mobile device and take a photo of each bowel movement using the Dieta application
- Primary Outcome Measures
Name Time Method Achievement of daily stool goal 4 weeks Number of subject to achieve daily stool goal, determined if use of the mobile application leads to improved rates of meeting daily stool goal (3-4 stools per day of Bristol Stool Scale 3-4)
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Mayo Clinic Rochester
🇺🇸Rochester, Minnesota, United States